Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 7,226 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control of Symptoms Clear all
Completed Phase 2 Interventional Results available

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

NCT00600119
View directory record Official record
Conditions
Opioid Induced Constipation (OIC)
Interventions
placebo, NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

NCT06415019
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery

NCT00399568
View directory record Official record
Conditions
Postoperative Pain, Hysterectomy
Interventions
IV Acetaminophen, IV Placebo 100 mL solution
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 3 Interventional

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

NCT00660959
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume
Interventions
lixivaptan, placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

NCT03034018
View directory record Official record
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pomegranate Products for Prevention of Common Cold

NCT00617318
View directory record Official record
Conditions
Influenza, Common Cold, Cough, Headache, Fever
Interventions
Pomegranate, Placebo
Dietary Supplement
Lead sponsor
Texas Heart Institute
Other
Eligibility
21 Years to 49 Years
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 1, 2026, 2:31 PM EDT
Withdrawn Phase 2 Interventional

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

NCT00506610
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
T-62
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Bradenton, Florida • Naples, Florida • New Port Richey, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 1, 2026, 2:31 PM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 1, 2026, 2:31 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD6793, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

NCT00766038
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

NCT01520649
View directory record Official record
Conditions
Depression
Interventions
NSI-189 Phosphate, microcrystalline cellulose capsules
Drug
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 1, 2026, 2:31 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058
View directory record Official record
Conditions
Obesity or Overweight, Type 2 Diabetes Mellitus
Interventions
Placebo, Enicepatide
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
42
States / cities
Guntersville, Alabama • Tucson, Arizona • Lake Forest, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

NCT06693648
View directory record Official record
Conditions
Osteoarthritis of Knee, Osteoarthritis, Knee
Interventions
AMZ001 Diclofenac gel, Placebo gel
Drug
Lead sponsor
Amzell
Industry
Eligibility
40 Years to 85 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Thousand Oaks, California • Hialeah, Florida • Longwood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013
View directory record Official record
Conditions
Obesity, Obese, Overweight or Obesity
Interventions
Bimagrumab, Semaglutide, Placebo
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

NCT00374920
View directory record Official record
Conditions
Bipolar Disorder With Manic or Mixed Episodes
Interventions
MEM 1003
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

NCT04533529
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Anaheim, California • Cerritos, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

NP2 Enkephalin For Treatment of Intractable Cancer Pain

NCT01291901
View directory record Official record
Conditions
Intractable Pain, Neoplasms
Interventions
NP2, Placebo
Biological
Lead sponsor
Diamyd Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Corona, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

NCT05075408
View directory record Official record
Conditions
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
47
States / cities
Bakersfield, California • Glendale, California • La Palma, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study

NCT05792176
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Music Training Intervention, Music Listening
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Mitigating the Impact of Shoulder Movement Dysfunction; a Randomized Controlled Trial

NCT04852640
View directory record Official record
Conditions
Shoulder Injuries, Shoulder Pain
Interventions
Active Rehabilitation Program (ARP), Nonspecific Passive Intervention (NPI)
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 1, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

NCT00404391
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Owing Mills, Maryland • Austin, Texas • San Marcos, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 1, 2026, 2:31 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 1, 2026, 2:31 PM EDT
Terminated Phase 4 Interventional Results available

A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

NCT01797380
View directory record Official record
Conditions
Depression, HIV
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 1, 2026, 2:31 PM EDT